Bright Minds Biosciences recently announced significant progress with BMB-101 as a potentially effective treatment for Dravet Syndrome. Because this rare form of epilepsy is not well understood, our Chief Medical Officer, Dr. Revati Shreeniwas, MD, FCCP, prepared this background. Dravet Syndrome is a rare form of severe pharmacoresistant epilepsy with onset in early childhood.…
Vancouver, BC – December 6, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual…
With the COVID-19 pandemic upending life in every corner of the world and putting unwelcome pressure on people vulnerable to depression, suicide and addiction, there has never been a better time to consider new treatments for mental health challenges. One field gaining particularly rapid traction is psychedelics. Of course, substances such as LSD and…
×
"*" indicates required fields